<DOC>
	<DOCNO>NCT02333058</DOCNO>
	<brief_summary>The primary goal study evaluate alternative myeloablative , reduce toxicity condition regimen child , describe safety efficacy intravenous ( i.v . ) Treosulfan administer part standardise Fludarabine-containing condition contribute current pharmacokinetic model able finally give age ( body surface area ) dependent dose recommendation . The treatment regimens give protocol MC-FludT.17/M base sufficient clinical safety efficacy data . Considering vital indication allogeneic haematopoietic stem cell transplantation select patient population , risk-benefit assessment therefore reasonably favour study conduct .</brief_summary>
	<brief_title>Treosulfan-based Conditioning Paediatric Patients With Haematological Malignancies</brief_title>
	<detailed_description>The protocol MC-FludT.17/M clinical phase II trial describe safety efficacy Treosulfan-based conditioning therapy prior allogeneic haematopoietic stem cell transplantation ( allo-HSCT ) least 70 paediatric patient haematological malignancy ( male female child haematological malignant disease acute lymphoblastic leukaemia ( ALL ) , acute myeloid leukaemia ( AML ) , myelodysplastic syndrome ( MDS ) juvenile myelomonocytic leukaemia ( JMML ) , require myeloablative conditioning treatment follow allo-HSCT ) . Treosulfan dose per day calculate use body surface area ( BSA ) . Two background condition regimen Treosulfan allow : One regimen consist standardise Fludarabine-containing regimen consist intensified regimen Fludarabine ThioTEPA . Freedom transplant ( treatment ) -related mortality ( TRM ) , define death transplant-related cause day first administration study medication day +100 HSCT primary objective trial . Moreover , current pharmacokinetic ( PK ) model contribute able finally give age ( BSA ) dependent dose recommendation .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Juvenile</mesh_term>
	<mesh_term>Hematologic Neoplasms</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Treosulfan</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>1 . Haematological malignant disease i.e . ALL , AML , MDS JMML , indicate alloHSCT . 2 . Indication first alloHSCT second alloHSCT due disease relapse , graft failure , secondary malignancy previous HSCT . 3 . Available match sibling donor ( MSD ) , match family donor ( MFD ) match unrelated donor ( MUD ) . For bone marrow ( BM ) peripheral blood ( PB ) match define 9/10 10/10 allele match four digit type human leucocyte antigen ( HLA ) A , B , C , DRB1 DQB1 . 4 . Patients ALL AML complete morphologic remission ( blast count &lt; 5 % BM ) patient MDS JMML blast count &lt; 20 % BM study entry . 5 . Age time registration 28 day less 18 year age . 6 . Lansky ( patient age &lt; 16 year ) Karnofsky ( patient age ≥ 16 year ) performance score least 70 % . 7 . Written inform consent parents/ legal guardian patient 's assent/consent accord national regulation . 8 . Females childbearing potential male patient ' partner childbearing potential must use highly effective method contraception ( pearl index &lt; 1 % ) complete sexual abstinence , combine oral contraceptive , hormone intrauterine contraceptive device ( IUCD ) , vaginal hormone ring , transdermal contraceptive patch , contraceptive implant depot contraceptive injection combination second method contraception like condom cervical cap / diaphragm spermicide surgical sterilisation ( vasectomy ) male patient male partner study least 6 month thereafter . 9 . Negative pregnancy test female childbearing potential . 1 . Third later alloHSCT . 2 . HSCT haploidentical umbilical cord blood donor . 3 . Symptomatic involvement central nervous system ( CNS ) study entry . 4 . Treatment cytotoxic drug within 10 day prior day 7 . 5 . Obese paediatric patient body mass index : weight ( kg ) / [ height ( ) ] ² &gt; 30 kg/m² . 6 . Solid tumour ( e.g . neuroblastoma , peripheral neuroectodermal tumour [ PNET ] , Ewing sarcoma ) . 7 . Fanconi anaemia deoxyribonucleic acid ( DNA ) breakage repair disorder . 8 . Impaired liver function indicate Bilirubin &gt; three time upper limit normal ( ULN ) aspartate aminotransferase/alanine aminotransferase ( AST/ALT ) &gt; five time ULN , active infectious hepatitis . 9 . Impaired renal function indicate estimate glomerular filtration rate ( [ GFR ] , accord Schwartz formula ) &lt; 60 mL/min/1,73m2 . 10 . Impaired cardiac function : severe cardiac insufficiency indicate left ventricle ejection fraction ( LVEF ) &lt; 35 % . 11 . Requirement supplementary continuous oxygen . 12 . Severe active infection require deferral conditioning . 13 . Human immunodeficiency virus ( HIV ) positivity . 14 . Known pregnancy , breast feeding . 15 . Known hypersensitivity Treosulfan and/or Fludarabine .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>ALL</keyword>
	<keyword>AML</keyword>
	<keyword>MDS</keyword>
	<keyword>JMML</keyword>
</DOC>